Developing a Long Term Strategy for a Warehouse Network

by

Patrick Johnson

B.S. Industrial and Systems Engineering, Auburn University, 2008

Submitted to the Sloan School of Management and the Institute for Data, Systems, and Society in partial fulfillment of the requirements for the degrees of

Master of Science in Engineering Systems
And
Master of Business Administration

In conjunction with the Leaders for Global Operations Program at the Massachusetts Institute of Technology

June 2017

© 2017 Patrick Johnson. All rights reserved.

The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part in any medium now known or hereafter created

Signature of Author ____________________________________________________________

MIT Sloan School of Management, Institute for Data, Systems, and Society
May 12, 2017

Certified by ________________________________________________________________

David Simchi-Levi, Thesis Supervisor
Professor of Engineering Systems, Institute for Data, Systems, and Society

Certified by ________________________________________________________________

Donald Rosenfield, Thesis Supervisor
Senior Lecturer, MIT Sloan School of Management

Accepted by ________________________________________________________________

John N. Tsitsiklis, Clarence J. Lebel Professor of Electrical Engineering
IDSS Graduate Officer

Accepted by ________________________________________________________________

Maura Herson, Director, MBA Program
MIT Sloan School of Management
This page intentionally left blank.
Abstract

This thesis addresses the question of how to create a pro-active, long term, network centric warehouse strategy. This thesis will present an inventory model built to understand the capacity needs of Amgen’s warehouses over the time period of 2017-2023 to support this mission, along with recommendations based on scenario analysis from this model to analyze and quantify the impacts of multiple scenarios in support of an efficient, effective, nimble supply chain.

With worldwide operations supporting a global customer base, Amgen’s operational philosophy is to ensure serving “every patient, every time”. Amgen’s warehouses play a vital role with this mission, storing raw materials to ensure production with safety stock and various levels of Work in Progress (WIP) based not only on operational safety stock, but also strategic safety stock to ensure demand is always met, even with unforeseen risks.

In order to understand the impacts of growth on warehouse utilization, a relational database inventory model was created and linked to the long range forecast of supply and demand. This inventory model linked the Bill of Materials (BOMs) to the product forecast in order to understand the quantity of raw materials required to meet the supply. The database also calculates the WIP and finished product levels of Amgen’s products. This model considers inefficiencies in the warehouses, as warehouse pallet spaces do not always store the maximum capacity of the material.

This inventory model calculated the capacity required for each warehouse over the forecasted ranges of FY 2016 to FY 2023. The findings of this model were used to create Amgen’s long term warehouse strategy. The model demonstrated a +10% accuracy to 2017 planning.

We developed a strategy that mimics Amgen’s operational strategy. Amgen’s operational strategy is to reduce fixed costs, and focus on flexibility with variable based costs. Based on this, we found the best strategy was to work with 3rd party logistics providers (3PLs) to mitigate the capacity gaps in a variable based manner. This option is preferred over investing in expanding capacity at warehouses already in use for all three scenarios of optimistic, baseline, and pessimistic demand profiles.

The biggest lever to gain warehouse capacity is to improve inventory policies and the flow of communication. Inventory policies whose aim is to reduce inventory can be viewed as a sensitive topic at a company like Amgen. But, if done in a scientific manner, and moving from a Months on Hand (MOH) approach to a scientifically calculated inventory, then moving to a multi-echelon inventory optimization, inventory and risk can be reduced. The following are ways that can be used to reduce inventory and risks.

- Track forecast error to understand variation of demand
- Lead time reduction of raw materials and work in progress
- Risk Pool Drug Product (DP) “nude” vials and decrease lead time from DP to customer
- Re-order point frequency increases
- Reduction of demand variability through:
  - Better communication of demand forecasts between marketing, global supply chain and site supply chain teams.
  - Reducing variability of manufacturing planning
- Seek commonality of raw materials to lower safety stock levels
- Multi-Echelon Inventory Optimization
By accomplishing these activities, Amgen has a scope to reduce 3PL storage requirements by 20k pallet-year spaces over the same time period. This will lower the expense of 3PL costs, and overall risks, over the same time period by $11 M. Considerable work will have to be accomplished, but the benefits will outweigh the costs.

Thesis Supervisor: Donald Rosenfield
Title: Senior Lecturer, MIT Sloan School of Management

Thesis Supervisor: David Simchi-Levi
Title: Professor of Engineering Systems, Institute for Data, Systems, and Society
Acknowledgements

No man is an Island - John Donne

I’d like to thank the Leaders for Global Operations Program for its support of this work. Amgen has been a gracious company throughout this project with support, encouragement, and proper feedback. More specifically, I’d like to thank Delia Sander for her never-ending support with all of the knowledge and experience she brought to this project. Tarun Bhatia was instrumental in keeping the high level impact of this project at the forefront, ensuring we focus on the big picture. As the saying goes, “I apologize for the long letter, as I didn’t have the time to write a shorter one.” Tarun has ensured we communicated the main message of this project to the network effectively. Venkat Subramanian was a tremendous help in ensuring focus and support on this project, navigating a tricky software procurement process with ease. Cathryn Shaw-Reid was gracious with her time sharing the bigger impact of how this project fits in with Amgen, and how I can help support that mission.

David-Simchi Levi, Sean Willems, and Donald Rosenfield, three brilliant professors, were always just an email or phone call away to offer light when I seemed lost in the dark. Two LGO alumni, Steve Fuller and Seth White, were so important in helping to determine which data to use to support the model displayed in this paper and where to find it. They also ensured I understood the limitations of this data.

Lastly, I’d like to thank Megan Johnson for her constant encouragement and support, being patient as I ruined another hike with her by thinking out loud about the intricacies of the model developed in this paper. She has always been ready for another adventure, and this certainly was one as we moved across the country to pursue this challenging opportunity.
# Table of Contents

Abstract ........................................................................................................................................ 3

Acknowledgements .................................................................................................................... 5

Table of Contents ....................................................................................................................... 6

List of Tables .............................................................................................................................. 8

List of Figures ............................................................................................................................ 9

List of Equations .......................................................................................................................... 10

1 Introduction ............................................................................................................................... 11

   1.1 Project Situation .................................................................................................................. 11

   1.2 Project Motivation ............................................................................................................. 12

   1.3 Problem Statement .......................................................................................................... 12

   1.4 Thesis Goals ..................................................................................................................... 12

   1.5 Thesis Scope .................................................................................................................... 13

   1.6 Thesis Overview .............................................................................................................. 13

2 Operations at Amgen ................................................................................................................ 14

   2.1 Company History ............................................................................................................ 14

   2.2 Company Therapeutics .................................................................................................. 15

   2.3 Operations Overview ...................................................................................................... 18

   2.4 Manufacturing Overview ................................................................................................ 21

   2.5 Warehouse Operations Overview .................................................................................... 24

   2.6 Supply Chain Operations Overview .................................................................................. 27

   2.7 Long Range Plan Overview ............................................................................................. 31

3 Literature Review ...................................................................................................................... 33

   3.1 Amgen’s Operations in Literature .................................................................................... 33

   3.2 Broader Themes in Literature relevant to this case ......................................................... 34

4 Methodology ............................................................................................................................. 42

   4.1 Current State Analysis ...................................................................................................... 42

   4.2 Baseline Warehouse Capacity Model Creation .............................................................. 43

   4.3 Warehouse Capacity Scenario Creation ......................................................................... 48

5 Results and Recommendations ................................................................................................ 52

   5.1 Model Results ................................................................................................................. 52

   5.2 Warehouse Strategy Creation .......................................................................................... 54
5.3 Supply Chain Communication .................................................................................. 56
5.4 Risk Mitigation Plan .................................................................................................. 57

6 Future Work ................................................................................................................. 57

7 Conclusion ..................................................................................................................... 59

8 References ....................................................................................................................... 62

Appendix 1: Warehouse Capacity Model Details ............................................................ 64

Baseline Model ................................................................................................................. 65
  Inputs: ............................................................................................................................ 65
  Queries: .......................................................................................................................... 65
  Outputs: ......................................................................................................................... 67

Risk Assessment .............................................................................................................. 67
  Inputs: ............................................................................................................................ 68
  Queries: ........................................................................................................................ 68
  Outputs: .......................................................................................................................... 68

Optimistic and Pessimistic Scenarios .............................................................................. 68
  Inputs: ............................................................................................................................ 68
  Queries & Outputs: ......................................................................................................... 68
List of Tables
Table 1: Comparison of Amgen’s Financial Metrics vs. Other Bio-tech Companies ........................................... 21
Table 2: Comparison of Safety Stock levels through lead time reduction .......................................................... 40
Table 3: Column Name and Column Descriptions of model output .................................................................. 52
Table 4: Capacity Utilization of baseline model for each warehouse by temperature type ............................... 53
Table 5: Model Predictions of over-utilization associated expense based on demand scenarios .................. 53
Table 6: Model predictions of over-utilization associated expense of warehouse network ............................ 54
Table 7: Site NPV 3PL expense based on demand scenarios .............................................................................. 58
List of Figures
Figure 1: Breakdown of Amgen’s Therapeutics by Revenue for FY 2015 (Amgen, 2016) ......................... 16
Figure 2: Conditional Probability of Success for Drug Trials 2000-2013 ............................................ 17
Figure 3: A Simplified Example of Amgen’s Supply Chain Operations .................................................. 20
Figure 4: Manufacturing Process Flow of Bio-Technology and the Corresponding Inventory ................. 22
Figure 5: Hypothetical Material Consumption Forecast ........................................................................... 23
Figure 6: cGMP Raw Material Checklist ................................................................................................. 25
Figure 7: Global View of Amgen’s Commercial Manufacturing, Warehousing, and Distribution Centers 26
Figure 8: Distribution of Last Stock Placement (in Days) for Amgen’s Warehouses ............................ 27
Figure 9: Amgen’s Work in Progress Inventory Levels ............................................................................ 28
Figure 10: Distribution of frequency of lead time (in days) of raw materials ....................................... 31
Figure 12: The Three Frontiers of Inventory Optimization (Willems, 2015) ............................................ 36
Figure 13: Example of a bull whip effect from point of sale to manufacturer ......................................... 37
Figure 11: Biopharma demand and forecast variation analysis (Rosenfield, 2014) ................................. 39
Figure 14: Demand Profiles for Optimistic and Pessimistic Pipeline and Commercial Therapeutics ....... 49
List of Equations

Equation 1: Average Cycle Stock Calculation .................................................................................. 28
Equation 2: Order Size Calculation ................................................................................................. 28
Equation 3: Calculation of Safety Stock .......................................................................................... 29
Equation 4: Calculation of Projected Balance .................................................................................. 32
Equation 5: Inventory equations from demand forecast and lead time ...................................... 39
Equation 6: Safety Stock Reduction through Lead Time Reduction ........................................... 40
Equation 7: Months on Hand Calculation ....................................................................................... 45
Equation 8: Calculations of Pallet spaces required for Pipeline Therapeutics with no known BOM’s... 45
Equation 9: Pallets of Projected Balance ......................................................................................... 45
Equation 10: Calculation of Raw Material ....................................................................................... 46
Equation 11: Calculation of WIP Inventory ..................................................................................... 46
Equation 12: Pallet Efficiency ........................................................................................................ 47
Equation 13: Warehouse Capacity Utilization ................................................................................ 47
Equation 14: Pallets over Capacity summation ............................................................................ 47
Equation 15: 3PL Cost for adding additional capacity .................................................................... 47
Equation 16: Net Present Value Calculation .................................................................................... 48
Equation 17: Equation for Commercial and Therapeutics Multiplier ............................................ 49
Equation 18: Warehouse Capacity Adjustment for Optimistic and Pessimistic Scenarios .......... 50
Equation 19: Warehouse Capacity Utilization at Standard Utilization ........................................... 51
Equation 20: Revised Pallets of inventory for Inventory Policy changes ......................................... 52
1 Introduction

1.1 Project Situation

*The sea gets deeper as you go further into it – Phoenician Proverb*

This thesis is a result of a research project with Amgen in Thousand Oaks, California as a fellow in the Massachusetts Institute of Technology Leaders for Global Operations program. The research project is a research-based component of the two year duel-degree program for a Masters of Business Administration and a Masters of Systems Engineering.

Amgen is a biopharmaceutical company whose mission is to “Serve Patients”. Their operating philosophy is to serve “every patient, every time”. They take this philosophy seriously, being only one of two bio-tech companies who have never stocked out of their life saving therapeutics for patients. This philosophy is shown in the balance sheet, with over $2.4B in inventory on $20.9B of revenue for Fiscal Year (FY) 2015 (Amgen, 2016). Amgen has a network of global warehouses that store inventory in support of this mission. These warehouses not only store raw materials with the corresponding operational safety stock and work in progress (WIP), but also strategic safety stock. This strategic safety stock is WIP at different stages of manufacturing stored to ensure patients will be served if any manufacturing capacity is lost to unplanned risks.

Amgen has a highly variable ten year forecast of their existing therapeutics, called the Long Range Plan (LRP) due to the following:

- A strong pipeline of developing drugs that may or may not be approved by the FDA.
- A propensity for acquisitions of other late stage drug therapeutics from other companies.
- Offering its therapeutics to more global markets, serving more countries.

Amgen currently has an excel-based model for individual warehouses that will show capacity utilization monthly over a rolling two years, but no pro-active, network-centric model or warehouse
strategy exists in support of the Long Range Plan. Due to this, warehouse managers and global supply chain managers make sub-optimal decisions when it comes to the storing of therapeutics, where some warehouses buy extra capacity in their respective local markets due to being over utilized, while at the same time other warehouses are underutilized.

1.2 Project Motivation
The motivation for this project is to ensure Amgen will be able to serve “every patient, every time” with a superior warehouse strategy. By creating a robust model that runs scenarios to simulate variations in demand profiles and changes in operating variables, an analysis can be created to identify over-utilization of capacity in the warehouse network and identify the best solutions to mitigate costly reactive decisions.

1.3 Problem Statement
Currently, there is no pro-active, long term, network centric strategy for Amgen’s warehouses. Warehouse managers manage their respective warehouses and supply chain managers flow their respective therapeutics through warehouses without regard to the entire network. This leads to some warehouses being over-utilized; which in turn leads to storage at 3rd Party Logistics providers (3PL’s); while other warehouses suffer from underutilization. Amgen forecast for future demand is highly variable, leading to reactive decisions in order to ensure warehouse capacity is available to store both raw materials and therapeutics.

1.4 Thesis Goals
The goal of this thesis is to create a warehouse strategy that will allow Amgen to nimbly, efficiently, and efficiently serve patients. To support this strategy, a model of the warehouse inventory requirements linked to Amgen’s Long Range Plan will need to be created. This model will identify the capacity gaps based on a variety of scenarios and the effects of capacity gap mitigations on the network.
Recommendations will be analyzed and given to ensure an efficient, effective, and nimble strategy is thoroughly communicated.

1.5 Thesis Scope

The scope of this analysis will be Amgen’s internal commercial production and warehouse system. More specifically, the capacity of Controlled Room Temperature (CRT)/Ambient and 2-8°C warehouse storage. Due to 3rd party manufacturing and distributors storing raw materials, WIP, and finished therapeutics at their own sites, they are out of scope. Due to the nature of clinical productions unknown demand and frequent schedule changes, clinical production and storage are out of scope. Also out of scope are the warehouse freezers and warehouse hazmat storage, as this storage is relatively small, and additional capacity can be added relatively quickly. The impacts of financial costs of moving inventory frictionless from one global location to another are also out of scope. Due to this significant factor, no new shipping lanes (nodes) were created or analyzed, as the impacts of the tax situation could possibly outweigh the benefits of lowering over-utilization.

1.6 Thesis Overview

This thesis is categorized by chapters in a way to understand the project first from a high level view of the industry and company, then dive deeper into the finer details of the warehouse strategy creation through model developed. The contents of each chapter can be briefly described as follows:

Chapter 2 will begin with an overview of the Amgen’s history, line of therapeutics, and future therapeutics. This chapter will also provide an overview of Amgen’s operations, and more specifically, warehouse and supply chain operations and the Long Range Plan.

Chapter 3 will provide a review of literature to showcase best practices for strategy creation and warehouse operations, along with a review of research on warehouse networks. It will also include a review of standard inventory policies.
Chapter 4 will detail the approach to solving the problem statement. This chapter contains the detailed steps of building the warehouse capacity model to support the strategy development, along with the equations. This chapter will also detail the scenarios built to understand the implications of changes in key assumptions in the model, along with scenarios to mitigate overutilization of the capacity.

Chapter 5 will detail the results and implications of the baseline model, along with the different scenarios. It will also detail recommendations for best practices and how to alleviate overutilization of the warehouse capacity. This analysis will be used to craft the strategy, which will be detailed.

Chapter 6 will detail future projects that could be taken on to ensure warehouse capacity is available in the foreseeable future, along with a path forward for inventory optimization to ensure an efficient, effective, and nimble supply chain.

2 Operations at Amgen

2.1 Company History

Amgen Inc. (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. William Bowes, a frustrated manager at Cetus Corporation (Author Unknown, 2016), left Cetus and recruited Winston Salser, a UCLA scientist, to begin Amgen in 1980. Bowes was able to recruit a powerful scientific advisory board and gain initial seed capital of $200K from venture capitalists. Bowes’ next step was to recruit George Rathmann from Abbott Laboratories to be the CEO of Amgen. Rathman was able to gain secured private equity funding from Abbot and Tosco Corporation, which gave confidence to venture capitalist, who in turn invested $19.4M in the new company. In 1983, Amgen tendered an IPO raising $42.3M.
With the financing now in hand, Amgen went to work on genetic engineering. Amgen was able to isolate and clone the erythropoietin gene, which stimulated red blood cell production. Since they had enough financing, they were able to forgo licensing the resulting drug (Epogen), and after a lengthy FDA approval process, gained the right to begin selling Epogen. In 1985, Amgen created a joint venture with Kirin Brewery to gain access to manufacturing technology in exchange for international marketing rights. With this manufacturing technology in hand, Epogen became the first biopharmaceutical to gross over $1B in annual revenue. Amgen has since grown to 20,000 employees with revenues of $21B for FY 2015 (Amgen, 2016), and a market cap of $128B.

2.2 Company Therapeutics

Amgen currently offers 15 innovative therapeutics with a wide variety of applications and modalities. Figure 1 describes the largest Amgen therapeutics by revenue and the corresponding revenue growth of those therapeutics. These therapeutics encompass every stage of the therapeutics life-cycle; from Epogen, which was approved for marketing in 1989 to Kyprolis, which was approved for treating patients with refractory multiple myeloma in 2016. These therapeutics are encountering growing competition as some therapeutics are coming off patent which brings on the creation of biosimilars. A bio-similar is a biological therapeutic that is highly similar to an FDA-approved biological therapeutics and has no clinically meaningful differences in terms of safety and effectiveness from the reference therapeutics (Amgen Pipeline, 2016).
Amgen’s main therapeutics, corresponding markets, and uses are the following:

- **Enbrel** – Marketed primarily in the United States, it is used primarily for the treatment of adult patients with the following conditions
  - Moderately to severely active rheumatoid arthritis,
  - Chronic moderate – to – severe plaque psoriasis patients
  - Active psoriatic arthritis

- **Neulasta** – Marketed primarily in the United States and Europe, it is used primarily to help reduce the probability of infection due to low white blood cell count in people with non-myeloid cancer who receive chemotherapy.

- **Aranesp** – Marketed primarily in the United States and Europe, it is used primarily for the treatment of anemia.

- **Epogen** – Marketed primarily in the United States, it is used primarily to treat a lower-than-normal number of red blood cells in patients on dialysis.
Sensipar/Mimpara – Sensipar is primarily marketed in the United States and Mimpara is primarily marketed in Europe. It is used primarily for the treatment of Secondary hyperparathyroidism in adult patients with Chronic Kidney Disease on dialysis.

Xgeva - Marketed primarily in the United States and Europe, Xgeva is used for prevention of bone failure in patients with bone metastases from solid tumors and

Prolia- Marketed primarily in the United States and Europe, Prolia is used for treatment of postmenopausal women with osteoporosis.

Neupogen – Marketed primarily in the United States, Canada, and Europe, it is used primarily to help reduce infection due to a low white blood cell count in people with non-myeloid cancer who receive chemotherapy.

In addition to a strong commercial offering, Amgen has 40 pre-clinical and clinical targets with strong genetic support (Amgen Pipeline, 2016). New and innovative therapies face regulatory approval from each market before being able to market to the general public. This process is risky, with the success rate estimated to be 9.6% (David W. Thomas, 2016), as detailed in Figure 2, and an estimated cost to bring one drug to market at capitalized cost of $1.8 B (Paul, et al., 2010).

Figure 2: Conditional Probability of Success for Drug Trials 2000-2013

Phase one clinical trials investigate safety and proper dose ranges of a therapeutics candidate in a smaller number of human subjects. Phase two clinical trials investigate side effect profiles and efficacy
of a therapeutics candidate in a large number of patients who have the disease or condition under study. Phase three clinical trials investigate the safety and efficacy of a therapeutics candidate in a large number of patients who have the disease or condition under study. As of November 2016, Amgen presently has fifteen therapeutics candidates in phase one trials, seven therapeutics candidates in Phase two trails, twelve therapeutics candidates in Phase three trails, and six therapeutics candidates being developed as Bio-similars. Based on the conditional probabilities for success from Figure 2 Amgen has an expected value of 8.4 novel therapeutics candidates emerging from trials to approval.

A bio-similar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has been previously been licensed by another company. Bio-similars follow a different regulatory review pathway than innovative therapeutics and indications. These products do not command the gross margins that patented products command, but do not face the high development costs, and risks that that entails, either.

### 2.3 Operations Overview

Amgen’s operational philosophy is to serve “every patient, every time”. They take great pride in focusing on the patient, with posters of patients around the office, and most staff meetings starting with patients talking about how Amgen’s therapeutics have positively impacted their lives. These words are not taken lightly, and this is shown in their balance sheet and operational strategy. Amgen uses inventory for the following reasons:

- Reduce risk of variation in demand
- Reduce risk of variation in supply
- Reduce risk of supplier shutdown’s for single-sourced suppliers
- Reduce risk of long, variable lead times
- Reduce risk of natural/geo-political manufacturing shutdowns
Certain variables add large uncertainty in the needs of warehouse utilization over the long term.

Amgen’s capacity utilization of its warehouses is growing over the next ten years due to the following:

- **Increased pack sizes of its therapeutics**
  Amgen’s marketing has identified that patients are looking for more than just the drug itself, valuing the esthetics of the package along with new technologies and drug delivery devices. New packs sizes to deliver these new devices can be 2 to 3 times larger than the traditional vials and syringes.

- **Therapeutics SKU growth for new markets**
  New markets are being developed, which adds complexity due to meeting new countries regulatory requirements.

- **New therapeutics being organically developed or acquired through acquisition.**
  As discussed in Figure 2, Amgen has a large pipeline of drugs that may or may not gain marketing approval from regulators. Amgen could also choose to acquire new promising late stage drug therapeutics.

- **Operations Strategy is changing from Large, Fixed Costs manufacturing to Disposable, Variable Cost manufacturing**
  Amgen is moving away from large, steel batch sized bio-reactors to disposable variable costs manufacturing in order to reduce the capital outlays and improve speed and flexibility to the patients. This technology has shown to require larger amounts of storage needs for raw materials.

- **Some of Amgen’s therapeutics are coming off patents, and the competitive space of the industry is increasing.**
  With a net profit margin of 33.13% for FY 2015 (Amgen Profitability Analysis, 2016), Amgen would only have to increase revenue by 3% (=.01/.3313) to achieve the same result as reducing operating costs by 1%. Clearly the larger the profit margins, the less important it is to focus on reducing operating costs. Therefore, when approaching this problem, costs are not the predominant factor in developing the strategy. The goal of the project is to ensure warehouse capacity under a variety of different scenario’s.

  Viewed through Amgen’s strategic lens, the operations team faces many challenges of organizational layout. Amgen’s greatly simplified supply chain organization is detailed in Figure 3.
Figure 3: A Simplified Example of Amgen’s Supply Chain Operations

Global sales, among other things, determines the forecast of demand for all of Amgen’s therapeutics. They communicate this demand to the global supply chain team. Under the Vice President of global supply chain, global supply chain managers determine the supply required by manufacturing to meet this demand, and which location of manufacturing and storage for each step of manufacturing. The raw materials & devices team handles the supplier relationships and sourcing opportunities, determines the strategy for raw materials, creates a high level inventory recommendation based on forecasted demand and supply, and then communicates these recommendations to the different manufacturing sites supply chain teams.

The different manufacturing sites supply chain teams review the recommendations for inventory levels, and fine-tune them based on their unique needs or constraints that are locally known.
They then place the orders into the ordering system to trigger the orders to the suppliers. The warehouse leader works with the site’s supply chain teams to understand the short term forecast in order to understand the warehouse capacity required to accept raw materials, work in progress, and finished therapeutics when it is shipped to them.

Amgen’s inventory turnover ratio is 1.74, leading to an average days of inventory at 210 days (Amgen, 2016). Based on a study performed in 2013 (REL, 2013), The U.S. Biotech industry has the 2nd highest Days of Working Capital (85 days) of all industries, right behind aerospace. Comparing inventory ratio’s to other bio-tech companies, Amgen has a lower inventory turnover, lower working capital turnover, higher days of inventory, and a longer cash conversion cycle, as shown in Table 1. While this table shows that Amgen has room for improvement among its peers, it should be noted that Amgen is only 1 of 2 bio-tech companies to have never stocked out of therapeutics to patients.

Table 1: Comparison of Amgen’s Financial Metrics vs. Other Bio-tech Companies

<table>
<thead>
<tr>
<th></th>
<th>AMGEN</th>
<th>Merck</th>
<th>Gilead</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventory Turnover</td>
<td>1.74</td>
<td>3.18</td>
<td>2.05</td>
</tr>
<tr>
<td>Working Capital Turnover</td>
<td>0.7</td>
<td>3.74</td>
<td>2.16</td>
</tr>
<tr>
<td>Days of Inventory</td>
<td>210</td>
<td>115</td>
<td>178</td>
</tr>
<tr>
<td>Cash Conversion Cycle (days)</td>
<td>179</td>
<td>113</td>
<td>137</td>
</tr>
</tbody>
</table>

2.4 Manufacturing Overview

Amgen’s manufacturing operations are a tremendous competitive advantage. The high level manufacturing flow for bio-tech begins with selecting a cell from a cell bank with the given medicinal properties. The cell is transferred to a beaker and fed various ingredients as the cell enters geometric growth. This growth is the bottleneck of the process, where cells double every 24 hours. The cells are systematically transferred to larger and larger vessels ensuring proper oxygen levels, pH, and temperatures for optimal growth. When the cell produces the protein, and the cells are at the necessary volume, the cell is broken up and the protein is harvested. Stabilizing ingredients are
introduced with the proteins to mitigate protein “clumping” and ensure the protein does not degrade over time. This solution is called drug substance (DS), and DS has a shelf life on average of 18 months.

Drug substance is sub-divided into patient sized syringes or vials and shipped to the next stage of manufacturing as drug product (DP). The DP can also be called “nude” vials, as they do not have market specific labels placed on these vials. The DP is packaged, labeled, and boxed to the final customer configuration with the proper instructions for that market and is prepared to be shipped as finished drug product (FDP) for the specific market(s) that Amgen serves. DP and FDP have a combined 24 months of shelf life. These steps detailed in Figure 4 have raw materials that flow in to support each process step, and each step has certain levels of WIP inventory, along with a strategic safety stock (SSS) to ensure that the philosophy of “every patient, every time” is met.

Figure 4: Manufacturing Process Flow of Bio-Technology and the Corresponding Inventory

Amgen’s operational strategy is transitioning from large fixed costs manufacturing as demonstrated in Amgen Rhode Island, which produces up to 10,000 kgs of DS in large steel vats to a variable costs manufacturing, as demonstrated in Amgen Singapore, which produces 2,000 kgs of DS in small, disposable bags for small batches. This variable cost production is a competitive advantage for Amgen for two reasons: speed and flexibility. The ability for Amgen to manufacture any therapeutic
rapidly is due to smaller, quicker manufacturing batches which can be used to meet demand for highly variable markets, and the disposable plastic bags can be set up quickly at greenfield sites in the event of manufacturing plants being incapacitated due to unforeseen risks. This new approach also has great environmental advantages such as a reduced footprint and reduced waste due to the reduced water and chemicals needed for cleaning large vessels.

Currently, the large fixed costs manufacturing is planned as campaigns. Since the manufacturing is batched, the demand for therapeutics, and the corresponding raw materials is also batched. This leads to manufacturing cycles like the following demonstrated in Figure 5. Manufacturing campaigns leads to difficulty in using standard deviations to calculate safety stock and leads to sites utilizing a different method in calculating safety stocks as detailed in Chapter 2.6. On top of this, manufacturing has been known to switch scheduled production runs due to not having raw materials for the baseline schedule.

**Figure 5: Hypothetical Material Consumption Forecast**
Variable cost production relies on one therapeutic being produced with a steady, non-variable production cycle. This deterministic manufacturing will ease the burden on the supply chain and allow for lower levels of operational safety stock.

2.5 Warehouse Operations Overview

Amgen is a global company with global operations, and as such has a global footprint. Amgen’s therapeutics are manufactured in 3 main manufacturing facilities and flows through 6 different warehouses. For FY 2015 (Amgen, 2016), Amgen stored $2.4B in inventory broken out in the following: $201M in raw material, $1.5B in work in progress, and $705M in finished therapeutics. Amgen has used this inventory very effectively, if not efficiently, being one of two biotech companies to have never stocked out of therapeutics to their customer.

These warehouses hold raw material, and different stages of work-in-progress and finished therapeutics; all which have different storage temperature requirements. All warehouses have the same basic layout and storage temperature types. The aggregated storage temperature requirements are the following:

- **CRT/Ambient** – This is Controlled Room Temperature/ Ambient warehouse space. This space is used to store mostly raw materials.
- **2-8°C** – This is cold storage warehouse space. This space is used to store mostly WIP from DP to FDP and finished therapeutics. There are some raw materials that need to be stored in this temperature range.
- **Freezers** – This space is either walk in freezers, or stand – up freezers that range from -10°C to -80°C. This is used to store mainly DS and certain DP and FDP
- **Haz-Mat** – This is a special case of the above temperature settings where acids, bases, and flammables must be stored in segregated areas for safety reasons
Warehouses in the biotech industry face a large set of requirements from the Federal Drug Administration (FDA) that ensures the safety and efficacy of the therapeutics to the consumer. These requirements contain guidelines and inspection requirements, and are listed in Figure 6.

**Figure 6: cGMP Raw Material Checklist**

| a) | Raw materials and primary packaging materials are stored and handled in a manner which prevents their mix-up, contamination with microorganisms or other chemicals, or decomposition from exposure to excessive heat, cold, sunlight or moisture. |
| b) | Containers of materials are closed, and bagged or boxed materials are stored off the floor. |
| c) | Containers of materials are labeled with respect to identity, lot identification and control status. |
| d) | Materials are sampled and tested or examined in conformance with procedures assuring the absence of contamination with filth, microorganisms or other extraneous substances to the extent necessary to prevent adulteration of finished products. |
| e) | Materials not meeting acceptance specifications are properly identified and controlled to prevent their use in cosmetics. |

Current Good Manufacturing Practice (cGMP) guidelines are set by FDA. Other considerations for warehouse operations is storage of Non-Bill of Material (BOM) related items like cleaning solutions and PPE, Material samples for quality tests, and material and therapeutics rejection cages.

Amgen’s warehouse operations are broken into two types of warehouses. Amgen has warehouses that support the production system and distribution centers to store finished therapeutics before being sent on to the distributors, who usually have 2-3 weeks’ worth of inventory (Amgen, 2016) to buffer against demand variability. As shown in Figure 7, Amgen’s manufacturing, warehousing, and distribution center have global reach. One of the opportunities discussed is how to leverage the entire network of the storage facilities to lower over-utilization of the warehouses. This can be seen as a network problem.
Amgen has internal commercial operations and supporting warehouses in California, Rhode Island, Massachusetts, Kentucky, Puerto Rico, Ireland, The Netherlands, and Singapore. The California facility also provide clinical operations. This internal network plus its collection of contract manufacturers are webbed together to provide risk mitigation production capabilities to support the operating principle of every patient, every time. For manufactured WIP, once manufacturing produces the DS, DP, or FDP, the manufacturing sites warehouses will store the therapeutics for a certain time period to ensure that the quality inspections are verified, then pack for transportation by air, sea, or land to the downstream manufacturing centers warehouse for further processing or to be distributed to customers. The average number of days that a product will sit in the warehouse is 134 days, or 4.5 months. The warehouses receive raw materials from distributors, and then store these materials in the warehouse until manufacturing requests the materials. The warehouse operations team will pull the requested raw materials from pallets, and stage them for manufacturing to consume. The average number of days that a raw material will sit in the warehouse is 162 days, or 5.4 months. The distribution of days since last
movement is shown in Figure 8. Based on this analysis, there does seem to be a decent amount of outliers, as this distribution has very long tails. A project should be initiated to investigate if any of these outliers really need to be in the warehouses, or could they be scrapped to open up additional capacity.

**Figure 8: Distribution of Last Stock Placement (in Days) for Amgen’s Warehouses**

2.6 Supply Chain Operations Overview

Amgen utilizes the following three main types of inventory: cycle stock, operational safety stock, and strategic safety stock. Cycle stock is the average amount of inventory to meet demand between the production cycles. Operational safety stock is inventory stored to ensure the variation of supply and demand is met between the production cycles. Strategic safety stock is a special type of inventory for Amgen. It is used for risk mitigation purposes, to ensure that if a manufacturing site is unable to manufacture therapeutics due to geo-political concerns or natural disasters, the inventory will be able to supply demand until manufacturing is restored at the affected site or delegated to an
alternative site to meet demand. Figure 9 demonstrates the inventory stock levels that Amgen uses for production.

**Figure 9: Amgen’s Work in Progress Inventory Levels**

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum Level</td>
<td>Expiry minus shelf life requirements (Possible Scrap)</td>
</tr>
<tr>
<td>Upper Planning Limit</td>
<td>Lower Planning Limit + cycle stock requirements</td>
</tr>
<tr>
<td>Planned Average</td>
<td>Lower Planning Limit + 1/2 of cycle stock</td>
</tr>
<tr>
<td>Lower Planning Limit</td>
<td>Operational Safety Stock Target</td>
</tr>
<tr>
<td>Minimum Level</td>
<td>Inventory held to mitigate unknown risk</td>
</tr>
<tr>
<td>Cycle Stock</td>
<td></td>
</tr>
<tr>
<td>Operational Safety Stock</td>
<td></td>
</tr>
<tr>
<td>Strategic Safety Stock</td>
<td></td>
</tr>
</tbody>
</table>

**Cycle Stock:**

This inventory is the inventory used to fulfill the anticipated demand until more can be produced. The average cycle stock can be detailed in Equation 1.

**Equation 1: Average Cycle Stock Calculation**

\[
\text{Average Cycle Stock} = \frac{\text{Order Size}}{2}
\]

The order size can be calculated from a given order frequency and desired production level detailed in Equation 2.

**Equation 2: Order Size Calculation**

\[
\text{Order Size} = \frac{\text{Production Rate}}{\text{Order Frequency}}
\]
The order frequency is the number of orders per year, and the production rate is set as the supply required to meet the demand plus the strategic and operational safety stock.

**Operational Safety Stock:**

This inventory is kept on hand to manage the variability of supply and demand, along with allocations for scrap and quality issues that could occur. The centralized raw materials team utilizes Equation 3 to set safety stock levels. The Z value is the inverse of the cumulative standardized normal one-tailed distribution. Currently, Amgen utilizes a 95% probability, which translates into the value of 1.64. The question is whether a 95% value is appropriate. To address this, we can draw upon the concepts of the newsvendor problem. Given the critical fractile approach, which balances overage and underage costs, to inventory, Amgen’s optimal safety stock inventory levels can be found. The newsvendor model determines the service level that a company should utilize by finding the minimum cost between underserving the market leading to lost sales, and overserving the market leading to excess inventory and scrap. In the bio-tech industry, underserving the market could lead to much graver situations, including market backlash, loss of reputation for other products, accelerated regulatory approval of competitor products, and up to patient’s death, hence the philosophy of ensuring “every patient, every time”. Analysis of Amgen’s optimal service level based on the newsvendor problem was found to be 99% (Yang, 2015). Based on this analysis, Amgen is using the incorrect service level of 95%, but due to the site supply chain managers ordering more safety stock then prescribed, it is unclear whether the correct safety stock is being held. Manufacturing has been known to switch scheduled production runs due to not having raw materials for the baseline schedule.

**Equation 3: Calculation of Safety Stock**

\[ SS = \sigma_{demand} \times Z \times (Reorder \ time \ period + Average \ Lead \ time)^B \]

Where B ranges from 0.5 to 1
The B in this equation is based on risk-pooling theory and is described in more detail in Chapter 3. Reflecting on the operations philosophy of serving “every patient, every time”, and the newsvendor model results, manufacturing sites supply chain managers utilize safety stock to cover the most that could be needed, and usually does not consider the typical probabilistic approach dictated in Equation 3.

Factors that influence the site supply chain managers’ decisions are sourcing diversification, ease of sourcing, supplier financial health, and a history of supply disruptions. At Amgen, safety stock is combined with cycle stock and treated as a variable that could be known as Months on Hand (MOH) of inventory. This is basically a blanket setting to ensure that there is enough raw material inventory on hand for X months of production.

**Strategic Safety Stock:**

To calculate strategic safety stock inventory, a risk team calculates the probability of an event that would incapacitate the manufacturing plant; whether it be fire, flood, storm, geo-political, or other disaster. The time period until production can be restored at that site, or another site, is calculated from the time the event occurs to the time manufacturing capacity can be restored. The amount of inventory to ensure that the demand is met during that time period is calculated as months of forward coverage, or MFC. This inventory is stored for every stage of therapeutics work in progress from DS to FDP detailed in the above section, and is not to be utilized except for risk mitigation purposes. A project should be explored for understanding the Time to Survive (TTS) for each manufacturing plant and compared to the Time to Failure (TTF) to ensure TTS>TTF. This idea is explored in Chapter 3.

Amgen’s lead times for raw materials is widely variable, and with a median lead time of 61 days and an average lead time of 63 days. The distribution of lead times for raw materials is shown in Figure 10.
Based on this, significant opportunities do abound to reduce lead times, and correspondingly, safety stock levels at warehouses. This analysis is explained in Chapter 3.

2.7 Long Range Plan Overview

Amgen’s LRP is created by the sales and marketing organization in conjunction with the supply chain organization. This plan is updated multiple times throughout the year when new information is made available, such as new market opportunities or current commercial therapeutics are allowed to be marketed to new indications. It is important to note that no forecast error is created for successive iterations of the LRP. With a proper forecast error, scientific formulas for inventory could be created and utilized to better ensure “every patient, every time”.

The following bullets detail how each portion of the LRP is calculated:

- **Demand** - Marketing and supply chain managers build a ten year annual forecast of all customer demand from the different markets of each therapeutic over the next ten years. This is
aggregated for each manufacturing site and therapeutics and its respective demand for a given year.

- **Supply** - Operations calculates the downstream supply (i.e. in order to make 1,000 FDP, it requires X DP units and Y DS lots) required to make the final therapeutics to ensure demand is met plus a projected balance for risk mitigation, lead times, and anticipated scrap. This is aggregated from the separate markets for each manufacturing site based on its respective supply for a given year.

- **Projected Balance** - The projected balance is the amount of therapeutics that will be stored to ensure the variation of demand is met and provide risk mitigation of unforeseen events. This is detailed in Equation 4.

**Equation 4: Calculation of Projected Balance**

\[
Projected \ Balance_{Year} = Projected \ Balance_{Year-1} + Supply_{Year} - Demand_{Year}
\]
3 Literature Review

Research is to see what everybody else has seen, and to think what nobody else has thought.
- Albert Szent-Gyorgyi

Prior to and during the development of the warehouse strategy, and corresponding model to support the strategy, much effort was expended to research the existing approaches. We will start with research close to Amgen’s operations, then discuss the broader literature available to support a robust solution to the problem statement.

3.1 Amgen’s Operations in Literature

Two warehouse models have already been detailed from previous MIT Leaders for Global Operations program thesis. Jason Choi in “Raw Material Inventory Planning in a Serial System with Warehouse Capacity” (Choi, 2014) discusses the inventory management policies and corresponding warehouse capacity required for one warehouse at Amgen. To reduce inventory at that warehouse and gain additional capacity, Choi recommends the following:

- Batch size optimization based on available warehouse space
- Safety stock reduction due to removal of demand variability by fixing the production system
- Reduce Stock Keeping Units (SKU) complexity through commonality of raw materials, which will lead to lower levels of safety stock
- Utilize Vendor Managed Inventory (VMI) to reduce inventory
- Utilize 3rd party logistics (3PL) in series to minimize warehouse transfers

Maxine Yang realizes in “Optimization of Warehouse Operations and Transport Risk Mitigation for Disposable Bioreactor Bags to Support Launch of Amgen Singapore Manufacturing” (Yang, 2015) the significant amount of safety stock being held at a specific warehouse, forecast changes that increased the demand, and how Bill of Material (BOM) changes affected storage capacity. She then proposes an excel-based model that will calculate the storage requirements based on lot production rates,
capacities, efficiencies, and forward coverage (safety stock levels). Her model calculated warehouse over-utilization in the near future, and recommended the following steps to reduce overutilization.

- Store raw material inventory at supplier’s warehouses
- Reduce lead time of raw materials
- Increase raw material delivery frequency
- Random assignments of pallet spaces
- Utilization of 3PL to store materials
- Reduce testing and release times for raw materials

According to the World Bank (Unknown, The World Bank, 2016), the average time to build a warehouse is 160 days. This is widely variable across countries. An internal study (Unknown, 2007) at Amgen revealed the average fixed cost to build a warehouse is around $29M, with an average fixed cost per pallet location space is around $5,000 with a standard deviation of $2,700. Warehouses are capital intensive cost centers, and therefore are not readily invested in unless truly needed.

3.2 Broader Themes in Literature relevant to this case

When building a prediction model, a good starting point should be Daniel Kahneman’s and Amos Tversky’s, “On the Psychology of Prediction” (Tversky, 1973). They summarize that the best way to create a prediction is to perform the following steps:

1) Understand the prior information, or base rate.
2) Understand the specific evidence about the base case.
3) Determine the expected accuracy, or range, of the prediction.

Given this understanding, it’s important to understand the current state, the equations driving the current state, and for the predictor to give a knowledgeable range of the prediction to ensure a proper model. Tversky and Kahneman describe how graduate students were given information about a person who scored on the 99th percentile on an IQ test, but the test had a known error. The students were asked to estimate a range of the true IQ score. The students gave an interval that was equal
around the 99th percentile, not realizing that the average score was at the 50th percentile. Therefore, the range should have been a heavily tilted toward the base rate. This type of bias leads to faulty models.

Sean Willems states in his paper, “Demystifying Inventory” (Willems, 2015) that using metrics such as MOH are wrong.

“That is, the [MOH] is calculated by determining how many [Months] into the future existing inventory on hand can satisfy. This corporate metric, which has some value, reinforces the incorrect intuition to focus on forward-looking parameters when setting inventory targets. So while we have definitively shown that forward [Months] of coverage is a bad metric to use for inventory planning purposes, its value as a corporate metric reinforces its incorrect usages for safety stock target setting.”

He further states the hardest step in optimizing inventory across the end-to-end supply chain is moving from ad hoc unscientific MOH to a scientifically derived inventory targets. He recommends moving from the 1st frontier to a 3rd frontier of inventory optimization:

1) Ad Hoc “Heuristics” Inventory Policies
2) Single Stage Scientifically Calculated Inventory Policies
3) Multi-Echelon Inventory Policies

The implication of these stages are detailed in Figure 11.
Proper inventory levels have been detailed heavily in operations, and one of the more frequently studied issues is the bull whip effect. The bull whip effect is due to variations in demand travelling upstream in the distribution system. This leads to increases in variation at each step in the supply chain, leading to large swings at the source. Research indicates a fluctuation in demand of +/- 5% at the point of sale can lead to a +/- 40% change in demand at the source (Hau L. Lee, 1997). This can be pictured in Figure 12 to showcase how small changes in demand propagate through the supply chain. The consequence of this typically leads to either stock-outs or excessive inventory. To counteract this problem, it’s necessary to extend the visibility of customer demand as far back in the supply chain as
possible, and use proper demand driven inventory policies such as Kanban principles, and to align channels through such activities as Vendor Managed Inventory (VMI).

**Figure 12: Example of a bull whip effect from point of sale to manufacturer**

Probability Theory of Risk- Pooling is a proven method to reduce inventory while simultaneously reducing risk. Risk pooling effectively gives you lower inventory with a higher service level. As detailed in “Using Forecast Variability and Risk Pooling to Determine Optimal Safety Stock Levels within a Supply Chain” (Roza, 1998), the variance of the sum of two random variables is not the sum of the individual variances when correlation is present. More importantly, unless the variables are perfectly correlated, the sum of the standard deviations are larger than the standard deviation of the sums. This feature allows for a lower safety stock when delaying production to the next step when one step produces many varieties in the next step. For example, when delaying production of FDP at the nude vial stage, the amount of safety stock can be greatly reduced. Assume for a demonstration purpose, two markets of FDP for a single drug therapeutic, where each market requires different configurations of labeling and packaging. With no risk pooling, the probability that no stock-out will occur is $0.99 \times 0.99 = 98\%$ (assuming independence). The amount of inventory to be held would be $\text{Inv}_{\text{noriskpooling}} = \mu_1 + \mu_2 +$
With risk pooling, the probability of meeting demand with the each therapeutics inventory is 99%, and the amount of inventory to be held would be $ln \nu_{riskpooling} = \mu_1 + \mu_2 + Z(\sigma_T) \cdot \sqrt{r + l}$ where $\sigma_T = \sqrt{\sigma_1^2 + \sigma_2^2 + 2\rho_{12}\sigma_1\sigma_2}$, and $\rho_{12}$ is the correlation value between the demand of 1 and 2.  Given the ranges of 1 to -1 for $\rho_{12}$, the safety stock can range from a worst case of $\sigma_T = \sigma_1 + \sigma_2$ when $\rho_{12} = 1$ to the best case of $\sigma_T = \sigma_1 - \sigma_2$ when $\rho_{12} = -1$.

To understand the base case of inventory, an inventory model should understand how product demand is built up. Rosenfield states, (Rosenfield, 2014)

“\text{The driver of inventory is forecast error. If forecast error is high, then more inventories is required to address the uncertainties. To establish how inventory varies, [an] analysis of three types of relationships should be studied:}

\begin{itemize}
  \item The relationship between inventory and forecast error
  \item The relationship between forecast error and the lead time over which it is calculated
  \item The relationship between forecast error and product volume
\end{itemize}

First, inventory increases as forecast error increases, because reserve stocks or safety stocks are generally proportional to the magnitude of forecast error. Because reserve stocks or safety stocks are typically the predominant part of inventory, we assume that inventories will behave as reserve stocks behave and thus be proportional to the magnitude of the forecast error. We can thus use standard inventory models for safety or reserve stocks”

Rosenfield further states that the “\text{variance of the demand forecast is proportional to the average total demand. Hence the square root of the variance, the standard deviation, is proportional to the square root of the average total demand.” (Rosenfield, 2014) This leads to the same result of the equation detailed in the above paragraph. Not only does this mean that demand forecast should be proportional, but also that lead times should be proportional. Although these two relationships do not always follow a square root relationship, there is a concave relationship between demand variation and forecast error and lead times, which is due to correlations of these two variables. These concave
relationships can range from 0.5 all the way up to 1. Rosenfield follows this up by showing that the values should be 0.8 for the biopharma industry as shown in Figure 13.

Figure 13: Biopharma demand and forecast variation analysis (Rosenfield, 2014)

This shows that as demand increases, inventory should only increase by a factor of .8. This could also be stated as inventory as a percent of demand. This relationship can be expressed by the following:

**Equation 5: Inventory equations from demand forecast and lead time**

\[
\text{Inventory} = K \bar{D}^{-(1-\alpha)t^\beta}
\]

where \( K \) is a constant of proportionality depending on the variability of the demand and the service level (in our case the Z value). This is the basis for the equation detailed in **Equation 3**

Another valuable project that will allow better forecasting is to begin tracking of the LRP forecast error. Roza states in his paper (Roza, 1998) the following:

“While a forecast error that is different both in magnitude and direction for each [therapeutic] flavor makes [a company’s] current process chaotic, it is just the scenario that would make risk-pooling effective. Risk-pooling under these conditions would allow the negative correlation between demand streams to mitigate the individual forecast errors inherent in the current forecast. For example, if all the [therapeutics] were held in a generic format, the under forecast of one flavor would cancel the over forecast of another flavor. Even if the demand streams were independent of slightly positively correlated [the]
sheer aggregation tends to decrease total variability and thus the required safety stock.”

Lead time reductions also offer lower inventory levels and increased flexibility without any additional risk. This can be accomplished with better inventory management policies like implementing Kanban systems. With shorter lead times, production can choose to delay shipment of items they do not need until later if the production schedule needs to be shifted, providing flexibility. Shorter lead times also decreases the time an item is not exposed to risks in shipments. Given the calculation for safety stock levels in Equation 3, the equation for determining the safety stock reduction through lead time reduction is listed in Equation 6.

Equation 6: Safety Stock Reduction through Lead Time Reduction

\[ \Delta_{SS} = 1 - \left( \frac{L_{New}}{L_{Old}} \right)^B \]

Where \( B \) ranges from 0.5 to 1

Given this equation and a value of \( B \) as 0.7, Table 2 can be produced.

Table 2: Comparison of Safety Stock levels through lead time reduction

<table>
<thead>
<tr>
<th>Original Lead Time (Days)</th>
<th>Revised Lead Time (Days)</th>
<th>Reduction in Safety Stock (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>100</td>
<td>0%</td>
</tr>
<tr>
<td>100</td>
<td>90</td>
<td>7%</td>
</tr>
<tr>
<td>100</td>
<td>80</td>
<td>14%</td>
</tr>
<tr>
<td>100</td>
<td>70</td>
<td>22%</td>
</tr>
<tr>
<td>100</td>
<td>60</td>
<td>30%</td>
</tr>
<tr>
<td>100</td>
<td>50</td>
<td>38%</td>
</tr>
<tr>
<td>100</td>
<td>40</td>
<td>47%</td>
</tr>
<tr>
<td>100</td>
<td>30</td>
<td>57%</td>
</tr>
<tr>
<td>100</td>
<td>20</td>
<td>68%</td>
</tr>
<tr>
<td>100</td>
<td>10</td>
<td>80%</td>
</tr>
</tbody>
</table>

Multi-Echelon Inventory Optimization (Willems, 2015) is the third efficient frontier is the supply chain frontier. In this setting, we now optimize safety stock targets across the supply chain. This requires a new level of communication and management, coupled with a multi-echelon inventory optimization engine, to facilitate the determination and use of the new targets. By strategically placing safety stock
inventory in the supply chain nodes, safety stock could be reduced at other nodes due to the lead time of the safety stock being able to bridge the needs of the following nodes. This is best accomplished by decoupling safety stock before a major value add step of manufacturing where the product is relatively cheap, and removing safety stock at the following levels until safety stock is held for the customer. The mathematical basis of reducing inventory through multi-echelon inventory optimization is the same as risk pooling in the previous paragraphs on risk pooling, but instead of optimizing two stages of the supply chain, MEIO minimizes costs across the entire supply chain while still ensuring “every patient, every time”.

For the optimization of inventory in a multi-echelon system, the following optimization program should be used (Sean Willems, 2011):

\[
P = \min_{j=1}^{N} \sum c_j(S_l_j, S_j)
\]

s.t. \quad S_j - S_l_j \leq T_j \quad \forall \ j \in N

\quad S_l_j - S_j \geq 0 \quad \forall (i, j) \in A

\quad S_j \leq s_j \quad \forall i; \ \forall k \in N | (j, k) \in A

\quad S_j, S_l_j \geq 0, \text{integral} \quad \forall \ j \in N

Where \( T_j \) is the time required to complete the processing requirements of stage \( j \), \( S_l_j \) is the longest outgoing service time from upstream adjacent stages quoted to stage \( j \), \( S_j \) is the delivery time stage \( j \) quotes its adjacent downstream stages, and \( s_j \) is the maximum outgoing service time at stage \( j \). Each stage has a cost function \( c_j(S_l_j, S_j) \) which is a function of its incoming and outgoing service times, and is the costs of holding inventory at the stage.

The objection function minimizes the total stage cost. The first constraint ensures the outgoing service level for each node is below the quoted service time plus its own lead time. The second constraint ensures the incoming service level for each node to be at least as large as the longest outgoing service time quoted to the node. The third constraint enforces an upper bound on a demand nodes outgoing service time. The final constraints require service times to be nonnegative and integer.
Time to Survive (TTS) analysis could be used to right-size the strategic safety stock levels at Amgen (Simchi-Levi, 2010). Amgen has already analyzed and found the Time to Recovery analysis, which is the time it takes to recover manufacturing capacity after an unforeseen disaster to its supply chain. TTS represents the time a supply chain system can continue to operate while its sources of supply are disrupted. Instead of focusing and holding a strategic safety stock, Amgen could perform a study on the TTS of its supply chain, and as long as $TTS > TTR$, the strategic inventory above that mark could be reduced. This exercise could also be used to identify risks to the supply chain.

4 Methodology

4.1 Current State Analysis

Amgen’s current warehouse strategy is reactive, with each warehouse site director managing their individual warehouse capacity, with therapeutic supply chain managers flowing their respective therapeutics through specific warehouses. This is all done with limited communication among warehouses, reactive decisions to add capacity, no common tools among the warehouses to study improvements to capacity, and with little consideration of the network. This leads to network inefficiencies, with some warehouses being over utilized, resulting in costly 3rd party storage, while other warehouses are run at low capacities, meaning low economies of scale, especially for cold storage.

An existing warehouse capacity utilization model has been constructed for each individual warehouse on a rolling month to month 24 month forward looking basis. Amgen’s Operations Strategy Planning & Risk (OSPR) group created these models, and updates these models monthly based on new planning updates. OSPR has reached out to train each warehouse site to run the model, but the model complexity is a labor intensive, technically complex spreadsheet that most warehouse site personnel do not have the time to understand the complexity driving the model. The models are used by the sites to
help understand the capacity utilization of individual sites. Each site has a representative that works with the site director to ensure the model reflects reality, and is used to plan capacity upgrades.

4.2 Baseline Warehouse Capacity Model Creation

*A model is a lie that helps you see the truth* – Howard Skipper

In order to create a strategy for Amgen’s warehouse network, the networks capacity needs must be understood over the time period in question. In order to fulfill this need, a model was constructed to understand the capacity requirements over an 8 year period, understand what is driving the capacity, and understand the different scenarios to alleviate capacity overutilization. Chapter 4.2 will detail the baseline model creation through its inputs, queries, and outputs, along with the simulation of different scenarios for business case evaluation. The model was chosen to be created in Microsoft Access®, a relational database tool that allows large streams of data to be linked together for custom reports. Access was utilized due to the ease of use, ease of access (as this project was over a six month period, speed was essential), and its ability to integrate with other Microsoft Office tools such as Excel® which the OSPR group is more readily experienced in.

4.2.1 Model Inputs

The Baseline Warehouse Capacity model utilizes tables that were either variables that the model builder can update, or constants that come from planning. The following are tables with either a (V) to label it as a table that contains variables, or a (C) to label it as a table full of constants. The variable tables can be updated by the user to provide scenario based model runs. I.e. what would happen if each site warehouses would increase their pallet utilization to 85%?

**Site Planning Tables (C)** – These tables (1 table for each site) are from the LRP detailed in Chapter 2.7. They contain the total demand for each site therapeutics by therapeutics by year, the
supply by therapeutics being manufactured at that site for each year, and the projected balance being held on site each year.\(^1\)

**BOMs (C)** – This table is the Bill of Materials (BOMs) for each therapeutics. This provides the raw materials required with the quantity in order to make each therapeutics by site. This table also contains a normalized quantity of the required amount of raw materials required to make therapeutics. (i.e. In order to make 1,000 FDP units of Therapeutics A, utilize 2,000 of raw material A.)

**Material Master (C)** – This table provides the temperature requirements for every raw material and therapeutics, and the quantity of material or therapeutics that makes up a pallet.

**Warehouse Capacity and Pallet Utilization** – This table provides the pallet utilization (\(V\)) and capacity (\(C\)) of each warehouse by temperature storage type. The pallet utilization table details how efficient the warehouses are at storing pallets at an aggregate level. i.e. If a pallet space can hold 10 filters, but only 5 filters are stored there, the pallet utilization is 50%. Each warehouse provided its own pallet utilization that it calculated over the past six months by temperature storage type.

**Months on hand (V)** – This table is the months on hand (MOH) of raw material and therapeutics aggregated by material sub-group (i.e chemicals, excipients, filters...) or therapeutics by months on hand for each site. As detailed in Chapter 2.6, this is a combination of cycle stock and safety stock. As even sites supply chain managers do not use the standard equations to determine inventory levels, a formula was calculated to approximate the MOH. These values were calculated by comparing the average inventory on hand over time (minimum 6 months) to the supply required for that year by site. This calculation is detailed in Equation 7. The \(\text{Average (Actual pallets on hand)}_{\text{Matl,Sub,Group}}\) was found from the short term model for the 24 month period for each Matl_Sub_Group.

\(^1\) Note: Due to 2016 being 75% of the way done in October 2016, the 2016 year’s balance is only 25% of the annual. This leads to some interesting results for year 2016. The models output should only be considered for years 2017 onwards.
Equation 7: Months on Hand Calculation

\[ Months\ on\ Hand_{\text{Mat}_\text{Sub}\_\text{Group}} = \frac{\text{Average(Actual pallets on hand}_{\text{Mat}_\text{Sub}\_\text{Group})}}{(\text{Pallets required to meet annual Supply/12})} \]

Manual Updates (V) – This table is a catch all table used to allocate any non-BOM materials by year i.e. PPE, Shipping Containers, Quality Samples, and any other pallet space quantities that are word of mouth. To calculate the manual updates, the team worked with sites and future forecasts to find the average amount of pallets needed to allocate to warehouses over the next 8 years. This also included pipeline therapeutics that did not have BOM’s for the raw materials needs. To calculate this, the demand for the pipeline therapeutics was compared to a similar therapeutics with a known BOM, and the ratio of demands and raw materials MOH’s was used to find the unknown pallet spaces as detailed in Equation 8.

Equation 8: Calculations of Pallet spaces required for Pipeline Therapeutics with no known BOM’s

\[ \frac{\text{Demand}_{\text{Pipeline}}}{\text{Demand}_{\text{Similar Product}}} = \frac{\text{Pallet Spaces Required}_{\text{Pipeline}}}{\text{Pallet Spaces Required}_{\text{Similar Product}}} \]

4.2.2 Model Queries

There were over 30 queries created for this model due to the complexity of the BOM’s, detailing the inventory types, and creating custom reports based on customer requests. The following will be high level queries to determine the different types of inventory. Many sub-queries were created to filter out certain items for further processing or the author lacked the knowledge of how to simplify the queries.

Projected Balance – The projected balance of therapeutics to be stored at each site annually was converted to pallet quantities and matched with the storage temperature requirements as detailed in Equation 9.

Equation 9: Pallets of Projected Balance
Raw Materials – This section of the model utilized 18 queries to pull together all the raw materials required to be on hand to support the supply dictated from the LRP. The queries filter the LRP for the quantity to be manufactured (supplied) by product by site for a given year and determines the raw materials required to make that supply. This value is then multiplied by the MOH for each material sub group, and then divided by the quantity per pallet for each raw material. This is captured in Equation 10\(^3\).

Equation 10: Calculation of Raw Material

\[
Pallets of X Raw Material_{item,site,year} = \text{integer}
\left(\frac{\text{Supply Required}_{item,site,year} \times \text{Months on Hand}}{12 \times \text{Quantity per Pallet}}\right)
\]

Work in Progress – This section of the model determines the Work in Progress for each site. The time it takes from when a therapeutics is manufactured, stored at that manufacturing sites warehouse then shipped to the downstream manufacturing site’s warehouse before it is processed into its next steps.

Equation 11: Calculation of WIP Inventory

\[
Pallets of X WIP_{product,site,year} = \text{integer}
\left(\frac{\text{Supply Required}_{item,site,year} \times \text{Months on Hand}}{12 \times \text{Quantity per Pallet}}\right)
\]

4.2.3 Model Outputs

Total Storage Requirements – This combines the above queries plus the manual updates into one table. It also adjusts every pallet by the efficiency as detailed in Equation 12. This is each site’s pallet storage needs by temperature requirement over the next 8 years.

\(^2\) Note: Some queries had to filter out and convert kgs and liters of raw material ingredients into the material storage units of grams and milliliters by multiplying the amount by 1000
Equation 12: Pallet Efficiency

\[
Adjusted \ Pallet \ Quantity = \frac{Pallet \ Quantity}{Efficiency}
\]

Warehouse Capacity Utilization – This is the aggregated capacity utilization for each site and temperature requirement over 8 years by year. This is the summation of the adjusted pallet quantity divided by the capacity of that site as detailed in Equation 13.

Equation 13: Warehouse Capacity Utilization

\[
Warehouse \ Capacity \ Utilization_{site \ temp \ year} = \frac{\text{Sum}(Adjusted \ Pallet \ Quantity_{site \ temp \ year})}{Capacity_{site \ temp}}
\]

After compiling the results of the models, the summation of the pallets over capacity will be calculated for all warehouses. This will be used to showcase the over utilization changes in the network capacity. This equation is detailed in Equation 14: Pallets over Capacity summation

Equation 14: Pallets over Capacity summation

\[
Pallets \ Over \ Capacity_{\text{year}} = \sum_{\text{warehouse } i=0}^{\text{warehouse } i=n} Pallets \ over \ capacity_i
\]

To compare the overutilization effects to the costs of building extra capacity at a site to support the capacity needs, each warehouse secured bids for the costs to move a pallet from its warehouse to store it at 3PL. The costs were multiplied by the number of pallets needing to be stored at the 3PLs to give a financial picture of the decision of how to add capacity. This equation is detailed in Equation 15.

Equation 15: 3PL Cost for adding additional capacity

\[
Cost \ of \ 3PL_{\text{year}} = \prod_{\text{warehouse } i=1}^{n} Pallets \ over \ Capacity_i \ast Cost \ of \ storage_i
\]

\[3 \] This is up to the model creator, one can either scale up every pallet by the efficiency factor, or scale down the overall capacity based on the efficiency factor. (i.e. 1 pallet/ efficiency factor or capacity*efficiency factor )
The Net Present Value for each warehouses 3PL costs was discounted using a rate of 8% from 2016 to 2023, as shown in Equation 16.

**Equation 16: Net Present Value Calculation**

\[
NPV(n) = \sum_{t=0}^{n} \frac{Cost\ of\ 3PL_{year}}{(1 + .08)^t}
\]

4.3 Warehouse Capacity Scenario Creation

Now that the baseline warehouse capacity model has been created, different scenarios were created to understand the sensitivity of the model, and different scenarios. The following questions were asked, and the corresponding scenarios created to answer the questions.

1) What are the implications on the warehouse capacity if the LRP underestimates or overestimates the demand?

2) What are the implications on the warehouse capacity if the manufacturing risk mitigation strategies are implemented?

3) What are the implications on the warehouse capacity if work in progress inventory is stored at the upstream or downstream manufacturing sites?

4) What are the implications on the warehouse capacity if lean efforts at warehouses are able to achieve better efficiencies?

5) What are the implications on the warehouse capacity if inventory policies are adjusted to lower safety stocks of raw materials, WIP, and finished therapeutics?

4.3.1 Demand Fluctuations Scenario

In order to determine the impacts on warehouse capacity from demand fluctuations, a scenario was developed to determine the scope of warehouse capacity needs under optimistic and pessimistic
demand scenarios. The drug therapeutics was broken up into two different groups depending on their stage in the therapeutics lifecycle.

- Commercial therapeutics: Therapeutics in the mature stage of the lifecycle stage, which face a less variable demand profile in the future. These therapeutics have been on the market for at least five years, and have shown stable demand profiles over that time period.
- Pipeline therapeutics: Therapeutics in the introduction and growth stages of the lifecycle stage, which face a more variable demand profile in the future. These therapeutics have been on the market for less than five years, or still seeking regulatory approval for marketing these therapeutics.

The different therapeutics, and corresponding raw materials, demand requirements were multiplied by a multiplier which increasingly grew or shrank the further out in time the forecast was made. The multipliers are detailed in Figure 14 for the next eight years. Eight years was chosen as after eight years, the forecast error is too high to create meaningful strategic decisions. The multipliers are calculated by the following formula in Equation 17.

**Equation 17: Equation for Commercial and Therapeutics Multiplier**

\[
Multiplier_{(y+1)} = \begin{cases} 
Multiplier_y \times (1 \pm .1) & \text{for Commerical Products} \\
Multiplier_y \times (1 \pm .2) & \text{for Pipeline Products} 
\end{cases}
\]

**Figure 14: Demand Profiles for Optimistic and Pessimistic Pipeline and Commercial Therapeutics**
Once this multiplier is determined for the given year and therapeutics type, the new capacity requirements were determined by multiplying the multiplier to the year’s demand of that therapeutics. This is detailed in Equation 18.

**Equation 18: Warehouse Capacity Adjustment for Optimistic and Pessimistic Scenarios**

\[ \text{Adjusted Pallet Quantity}_{\text{year product}} = \text{Adjusted Pallet Quantity}_{\text{year product}} \times \text{Multiplier}_y \]

### 4.3.2 Risk Mitigation Scenario

For every manufacturing site and corresponding therapeutics, a risk plan has been created to ensure demand is met through a combination of strategic inventory, production lines at other sites, or contract manufacturing. These plans are documented in playbooks created by the risk team. To test the implications of the risk plans on warehouse capacities across the network, simulations were ran that changed the inventory of the warehouse from the site being under duress to its risk mitigation site warehouse. This was accomplished with a query with the following logic:

For each Site x Therapeutics i:

If Site x goes down for Therapeutics i,

Then Therapeutics i capacity moves to site x Therapeutics y’s risk mitigation site
### 4.3.3 WIP Storage at Upstream or Downstream Sites Scenario

This scenario explores delaying shipment of WIP inventory to the downstream warehouses if the downstream warehouse is at capacity, or expediting shipments of WIP inventory to the downstream warehouses if the upstream warehouse is at capacity. As shipping routes have already been established, proper communication between upstream and downstream planning teams could manage the level loading of the warehouses to ensure risk are mitigated. To analyze this, a heuristic was developed that followed the following logic:

1) Identify the warehouse that is most over-utilized for WIP
2) Identify the warehouse that is either upstream or downstream that is the most under-utilized for WIP
3) Identify the therapeutics that can be either delayed at the upstream warehouse, or expedited to the downstream warehouse.
4) Update the utilization of the warehouses and repeat until all warehouses are under capacity.

### 4.3.4 Pallet Utilization Gains at each warehouse Scenario

This scenario explores running each warehouse pallet utilization gains at an Amgen standard of 85%. This would entail a constant analysis of each warehouse with a software that will ensure that each pallet space will on average be utilized at 85% of its capacity. To simulate this, Equation 13 was updated to Equation 19.

**Equation 19: Warehouse Capacity Utilization at Standard Utilization**

\[
Warehouse\ Capacity\ Utilization_{site\ temp\ year} = \frac{\text{Sum}(\text{Adjusted Pallet Quantity}_{site\ temp\ year})}{.85}
\]

### 4.3.5 Inventory Policies Scenarios

This scenario simulates warehouse capacity utilization required if Amgen utilizes the equations recommended in the literature review to set safety stock levels. To simulate this, Equation 10 and Equation 11 were modified to the following equation:
Equation 20: Revised Pallets of inventory for Inventory Policy changes

\[ \text{Pallets of } X \text{ WIP and } RM_{\text{product site year}} = \text{Integer} \left( \frac{(\text{Supply Required}_{\text{item site}})}{\text{Quantity per Pallet}} \times \frac{(\text{Months on Hand} \times R^A)}{12} \right) \]

Where \( R \) = the ratio of demand of that year to the demand in 2016 (i.e. \( R_{2017} = \text{Demand (2017/2016)} \)) and A is a power of \( R \) - typically in the range of 0.5 to 1. Here we used a 0.7, a conservative number that says when demand is doubled, the safety stock will only rise by 70%. This equation ensures that the safety stock does not rise linearly with the demand, as the safety stock should rise with a power function as detailed in Equation 3 in Chapter 3.

5 Results and Recommendations

5.1 Model Results

The model results detailed the following items in Table 3 over the time period of 2016-2023. This output could be used to create pivot tables structured to understand the storage size across the different columns.

Table 3: Column Name and Column Descriptions of model output

<table>
<thead>
<tr>
<th>Column Name</th>
<th>Column Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site</td>
<td>A three letter identification detailing which warehouse the material is stored at</td>
</tr>
<tr>
<td>Site_Name</td>
<td>A three digit number detailing which warehouse the material is stored at</td>
</tr>
<tr>
<td>Mtrl_Grp</td>
<td>A three digit number detailing which product line the material supports</td>
</tr>
<tr>
<td>Material Group</td>
<td>A short hand identifier detailing which type of material stored</td>
</tr>
<tr>
<td>Mfg_Stage_Edited</td>
<td>A identifier which details which stage of manufacturing the material is supporting</td>
</tr>
<tr>
<td>Part Name</td>
<td>A name assigned to each unique part needing to be stored</td>
</tr>
<tr>
<td>Part_Description</td>
<td>A description of the unique part name needing to be stored</td>
</tr>
<tr>
<td>Q/Pallet</td>
<td>How many units of each part make up a full pallet equivalent (FPE)</td>
</tr>
<tr>
<td>High_Level_Temps</td>
<td>What temperature group the material is stored in</td>
</tr>
<tr>
<td>Quantity (By Year)</td>
<td>The quantity of pallets stored</td>
</tr>
<tr>
<td>Inventory_Type</td>
<td>A category detailing if the material is a raw material or product</td>
</tr>
<tr>
<td>Type</td>
<td>A category detailing if the material supports a commercial product, pipeline, or bio-similar</td>
</tr>
</tbody>
</table>

52
The model accuracy was compared to the short term models results, and was found to be +-10% for each of the matl_sub_groups from the years 2017 and 2018, which when aggregated, the overall model was +-10% for each site. Moving forward, the model should be re-ran every time the LRP is updated to determine the differences between the LRP.

The data was used to create multiple reports, most importantly the capacity utilization of each warehouse by temperature requirements. This information for the baseline model is shown in Table 4. This table shows a steady increase of warehouse utilization at most warehouses, and ABR and ASM running out of capacity in the near time.

Table 4: Capacity Utilization of baseline model for each warehouse by temperature type

<table>
<thead>
<tr>
<th>2-8C Utilization</th>
<th>Site</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td></td>
<td>79%</td>
<td>115%</td>
<td>62%</td>
<td>9%</td>
<td>47%</td>
<td>19%</td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td>60%</td>
<td>166%</td>
<td>76%</td>
<td>80%</td>
<td>14%</td>
<td>46%</td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td>58%</td>
<td>198%</td>
<td>88%</td>
<td>46%</td>
<td>81%</td>
<td>279%</td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td>67%</td>
<td>191%</td>
<td>95%</td>
<td>27%</td>
<td>67%</td>
<td>164%</td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td>68%</td>
<td>196%</td>
<td>95%</td>
<td>18%</td>
<td>61%</td>
<td>196%</td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td>68%</td>
<td>200%</td>
<td>96%</td>
<td>19%</td>
<td>63%</td>
<td>193%</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td>73%</td>
<td>202%</td>
<td>99%</td>
<td>19%</td>
<td>63%</td>
<td>200%</td>
</tr>
<tr>
<td>2023</td>
<td></td>
<td>73%</td>
<td>201%</td>
<td>101%</td>
<td>18%</td>
<td>65%</td>
<td>179%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CRT Utilization</th>
<th>Site</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td></td>
<td>37%</td>
<td>38%</td>
<td>48%</td>
<td>41%</td>
<td>13%</td>
<td>125%</td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td>66%</td>
<td>89%</td>
<td>42%</td>
<td>51%</td>
<td>46%</td>
<td>113%</td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td>59%</td>
<td>97%</td>
<td>13%</td>
<td>40%</td>
<td>60%</td>
<td>477%</td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td>58%</td>
<td>105%</td>
<td>14%</td>
<td>35%</td>
<td>70%</td>
<td>522%</td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td>62%</td>
<td>112%</td>
<td>9%</td>
<td>35%</td>
<td>67%</td>
<td>503%</td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td>64%</td>
<td>119%</td>
<td>7%</td>
<td>37%</td>
<td>67%</td>
<td>529%</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td>67%</td>
<td>123%</td>
<td>8%</td>
<td>38%</td>
<td>68%</td>
<td>542%</td>
</tr>
<tr>
<td>2023</td>
<td></td>
<td>68%</td>
<td>124%</td>
<td>7%</td>
<td>37%</td>
<td>68%</td>
<td>526%</td>
</tr>
</tbody>
</table>

Once the overall warehouse capacity utilization was found for the next eight years, and each scenario tested, a cost-benefit analysis was created. The utilization numbers were found for the optimistic, baseline, and pessimistic cases of warehouse utilization, the pallet-years over capacity, and the subsequent NPV to expense the 3PL storage to mitigate the over-utilization, were found to determine the decisions to make additional capacity by adding warehouse space, or buy capacity from a 3PL. The results of this analysis are shown in Table 5.

Table 5: Model Predictions of over-utilization associated expense based on demand scenarios

<table>
<thead>
<tr>
<th>Pallets over capacity</th>
<th>Pessimistic Demand</th>
<th>Baseline Demand</th>
<th>Optimistic Demand</th>
</tr>
</thead>
<tbody>
<tr>
<td>11,234</td>
<td>36,481</td>
<td>59,356</td>
<td></td>
</tr>
<tr>
<td>NPV of 3PL Expense</td>
<td>$7,013,928</td>
<td>$20,479,003</td>
<td>$46,705,991</td>
</tr>
</tbody>
</table>
Other scenarios identified in Chapter 4 assist to determine the best methods to mitigate overutilization were calculated for the quantity of pallet-years over capacity over the eight year period, and a NPV of the pallets to store at the 3PL’s for each warehouse. The results are displayed in Table 6. This shows that, out of the scenarios identified, inventory policies discussed in Chapter 3 are the biggest lever to reduce over-utilization and to reduce risks, followed by leveraging the existing network, and continuous improvement opportunities at the warehouse sites. By using a scientifically calculated inventory possibility, the over-utilization of the warehouses of the baseline demand could be reduced by over 50%, while better utilization of the network could reduce over-utilization by 12%. Note that this is not an either or option. All three policies could be simultaneously run to reduce overutilization.

Table 6: Model predictions of over-utilization associated expense of warehouse network

<table>
<thead>
<tr>
<th>Pallets over capacity</th>
<th>Baseline Demand</th>
<th>Inventory Policies</th>
<th>Network Leverage</th>
<th>Pallet Efficiencies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>36,481</td>
<td>16,652</td>
<td>31,872</td>
<td>33,219</td>
</tr>
<tr>
<td>NPV of 3PL Expense</td>
<td>$20,479,003</td>
<td>$9,431,232</td>
<td>$18,031,720</td>
<td>$18,903,658</td>
</tr>
</tbody>
</table>

5.2 Warehouse Strategy Creation
Amgen’s Executive Vice President is quoted saying, “the supply chain strategy should be aligned with the overall operations strategy”. Based on this, Amgen’s operations are transitioning to a modular, variable based production strategy, away from asset heavy, large, fixed - production systems. So must the warehouse strategy.

Given the results of Chapter 5.1, the analysis shows that the NPV of 3PL’s is lower than the expense of building additional capacity of warehouses for all scenarios as shown in Table 5. The analysis also shows the best way to mitigate overutilization of warehouse capacity would be to update the inventory policies. Amgen’s current practice is to use a flat MOH level for raw materials = {Cycle Stock} + {Operations Safety Stock}. That is, raw materials operational safety stock

---

4 This is calculated on by the benefit of the scenario. Costs were not considered, which could be a significant factor. As shown in Chapter 3, inventory policies could reduce risks, but must be considered thoughtfully.
inventory increases linearly with therapeutics demand. Using this logic in the model demonstrates that our current practice inventory increases proportionally with volume, but according to Equation 20, inventory should actually increase at a 0.8 power function of reorder frequency (which is a proxy for volume). The Raw Materials & Devices team recognizes this mathematical function and recommends it to the site supply chain teams, but the sites set their own (often proportional) levels. The opportunity of implementing the Operational Safety Stock based on the aforementioned power function is a theoretical $219M NPV (8%, FY 2017-2023) in lower working capital and a 3PL storage reduction of 6,000 pallet-year space across the network.

The opportunity from changing fixed MFC policy for therapeutics WIP and finished product Operational Safety Stock to one that varies at a 0.8 power function of volume opens up a large possible opportunity in less working capital and a 3PL storage reduction of 14,000 pallet-year fewer space across the network. This approach is made that much more powerful and reduces risk if Amgen increases nude DP by reducing FDP and focus on improving lead times from DP to customers. The mathematical driver is that risk pooling IDP across a larger market base will pool the variation utilizing the lessons in Chapter 3, further increasing the opportunity to decrease Operational Safety Stock, (and possibly Strategic Safety Stock). To affect this change, Amgen will have to become more nimble; quantitatively this means reducing L (lead time) and decreasing R by increasing reorder frequency. There will, undoubtedly, be many operational complexities, but the opportunity is large and worth exploring.

Amgen currently is using significant external warehouse space at Site B and Site E. This overutilization will increase significantly next year. Site E is forecasted to start drawing more heavily on external space next year (albeit, the space requirement based on the 5th pass 2016 LRP is less than forecast from the 1st pass). The current therapeutics flow is Site B (or supplier) >> Site D >> 3PL >> Site D. A better approach would be Site B (supplier) >> 3PL >> Site D. This would lower warehouse labor, transportation costs, and risk through 25% less movements. In order to accomplish this, a project would
have to be started at each warehouse, and SAP would have to be updated to reflect the inventory at 3PL’s.

One of the tenants of lean manufacturing is a production system must be set. Due to Amgen’s flexibility, the site supply chain managers have to be ready to produce any therapeutics when signaled to. This necessitates the need to carry a larger inventory of raw materials, and due to not knowing the next time therapeutics will be manufactured, a correspondingly high cycle and operational safety stock. By setting the production cycle, and having an agreed start date for manufacturing, the site supply chain teams will not have to store the inventory levels as high due to a lower variation of demand.

5.3 Supply Chain Communication

One of the best ways to prevent the dreaded bull whip effect as shown in Chapter 3 is proper communication between roles. Some pathways could be improved to foster better communication and results, such as the marketing team does not have an established communication pathway to each site’s raw materials team. This leads to therapeutics being offered at discounts or different configurations that quickly trigger unanticipated demand for raw materials, which drains safety stock due to the bull whip effect. This problem is explored and solved in in Chapter 3. In addition to financial repercussions, production could be more streamlined as production sometimes switches to product where the raw materials are on hand. In addition, workforce stress could be reduced, as scrambles by supply chain and manufacturing occurs to ensure production is not interrupted. The global supply chain managers also could work with warehouse managers, and warehouse managers with each other, to work at pooling raw materials and utilizing delay and push strategies for upstream and downstream material moves. By utilizing this strategy, the warehouses could free up ~ 5,000 pallet-years spaces and reduce 3PL costs by $2.5M over 8 years.
5.4 Risk Mitigation Plan

The risk mitigation plans that detail which sites manufacturing capacity would take over if another sites manufacturing capacity were brought down due to unforeseen risks were brilliantly analyzed, but did not consider the warehouse capacity to store the raw materials needed to produce the manufacturing. The analysis shows that most warehouses would not be able to support the risk mitigation plans due to being overcapacity. To counteract this over-utilization and ensure the warehouses will be able to support the added capacity, warehouse sites should create a risk mitigation plan and develop options with a local 3PLs to be able to store necessary raw materials.

6 Future Work

This strategy only goes so far in recommending high level decision making, while there are many projects that could be put into place that would further increase productivity and lower risk in the warehouse network. They include the following areas:

- Presently, the warehouses operate independently in identifying capacity overutilization, continuous improvement activities to lower the overutilization, and the selection and handling of inventory to a 3PL. Many activities must be standardized, including the following:
  - Overflow storage for all non-critical inventories
  - Overflow storage for all critical inventories
  - True overflow with a shuttle between site and overflow
  - SAP updates to factor inventory at 3PL sites
  - Standards on make vs. buy and the different trigger in risk, cost, quality, etc.

Another scenario that should be studied would be an expansion of a warehouse that is known to be over-utilized. Bids would need to be placed to add a specific amount of capacity, and then compared with the model’s NPV analysis of the cost of 3PLs for each site. The costs for each warehouse overutilization from the baseline models are shown in Table 7.
A wise man once said the following statement is always true, “You have roughly the right amount of inventory, you just have too much of some stuff and not enough of the other stuff” (Sean Willems, 2011). Much work could be started to look into the risk free methods of inventory optimization. Moving from the Ad Hoc Frontiers to the Supply Chain Frontiers can lower safety stock levels by 10-30%, while still ensuring “every patient, every time”. Simple projects such as risk pooling and lead time reductions can make a drastic improvement, and free up warehouse capacity while saving large amounts of working capital, and the subsequent holding cost. In order accomplish this, better communication between the marketing units and site supply chain teams must be made, and lean efforts to set the manufacturing schedule should be brought to minimize variation, and lead time reductions accomplished. To get started on a scientifically calculated inventory policy, tracking the errors of the LRP for each Stock Keeping Unit (SKU) should be accomplished to determine the demand variation. This could be a moving monthly or quarterly deviation from the forecast. After finding this value, it could be averaged out over time periods to determine the demand variation, which would be an input for the safety stock calculations in Equation 3.

Once this is accomplished establish the base case by calculating the existing average inventory level for each SKU. Next, scientifically calculate the expected inventory level using demand, lead-time, and service information. Next, compare the two numbers and deep dive the differences. Present the

---

5 Site C’s has no known 3PL costs right now, and the over-utilization even for the optimistic demand scenario of site C was minimal, so no calculation was performed.
detail but also offer general insights. As Sean Willems states, “convert data to information to knowledge to wisdom”.

Strategic safety stock is an appropriate risk mitigation strategy for the risk of loss of manufacturing capacity, but can be fine-tuned with Time to Survive (TTS) analysis. Amgen has accomplished a good job at calculating Time-to-Recovery (TTR), the time it would take for a particular node to be restored to full functionality after a disruption. An analysis of TTS, the maximum duration that the supply chain can match supply with demand after a disruption, will provide the proper amount of inventory to hold. Right now, Amgen utilizes strategic safety stock as the TTS, but do not utilize the operational cycle and operational safety stock in this analysis. Amgen should consider the operational cycle and safety stock as a TTS, and for the items that the TTS > TTR, an inventory reduction project could be started to mitigate the excess inventory.

7 Conclusion

In order to understand the impacts of growth on warehouse utilization, a relational database inventory model was created and linked to the long range forecast of supply and demand. This inventory model linked the Bill of Materials (BOMs) to the product forecast in order to understand the quantity of raw materials required to meet the supply. The database also calculates the WIP and finished product levels of Amgen’s products. This model considers inefficiencies in the warehouses, as warehouse pallet spaces do not always store the maximum capacity of the material. This inventory model calculated the capacity required for each warehouse over the forecasted ranges of FY 2016 to FY 2023. The findings of this model were used to create Amgen’s long term warehouse strategy. The models forecast demonstrated a +/- 10% accuracy to 2017 planning,

We developed a strategy that mimics Amgen’s operational strategy. Amgen’s Operational strategy is to reduce fixed costs, and focus on flexibility with variable based costs. Based on this, we
found the best action was to work with 3rd party logistics providers (3PLs) to mitigate the capacity gaps in a variable based manner. This option is preferred over investing in expanding capacity at warehouses already in use for all three scenarios of optimistic, baseline, and pessimistic demand profiles.

The biggest lever to gain warehouse capacity is to improve inventory policies and the flow of communication. Inventory policies whose aim is to reduce inventory can be viewed as a sensitive topic at a company like Amgen. But, if done in a scientific manner, and moving from a Months on Hand (MOH) approach to a scientifically calculated inventory, then moving to a multi-echelon inventory optimization, inventory can be reduced while also reducing risk. The following are ways that can be used to reduce inventory with little to no risk.

- Track forecast error to understand variation of demand
- Lead time reduction of raw materials and work in progress
- Risk Pool Drug Product (DP) “nude” vials and decrease lead time from DP to customer
- Re-order point frequency increases
- Reduction of demand variability through:
  - Better communication of demand forecasts between marketing, global supply chain, and site supply chain teams.
  - Reducing variability of manufacturing planning
- Seek commonality of raw materials to lower safety stock levels
- Multi-Echelon Inventory Optimization

Note that these are not either or choices, but can be combined projects to reduce risk and becoming operationally more efficient. By accomplishing these activities, Amgen has a scope to reduce working capital, reduce risk, and free up 20k pallet-year spaces over the same time period. This will also
lower the expense of 3PL costs and overall risks over the same time period. Considerable work will have to be accomplished, but the benefits will outweigh the costs.
References


Appendix 1: Warehouse Capacity Model Details

This is the user guide to update and maintain the Warehouse_Capacity_Model.accdb. This database is used to approximate the warehouse capacity over the long term by linking the Long Range Plan (LRP) and determining the inventory requirements based on BOMS and Safety Stocks. The database also has other tools, such as the following:

- Risk analysis, which determines the effects of a production sites mitigation efforts
- Optimistic and Pessimistic scenarios for pipeline and commercial therapeutics demand

The following user guide will show you how to understand the model, how to update the model, and how to get the most out of the model.
Baseline Model
This is the baseline model for the warehouse capacity. This takes the inputs of the
MPS_Summary_Reports from Rapid Response, and links the projected supply to the BOMS to determine
the inventory required to manufacture the supply, along with the required safety stock, and projected
balance of therapeutics on hand. All the queries and tables are built to sum up to the
FINAL_WAREHOUSE_CAPACITY_RESULTS query. This query will compile all updates and can be ran after
any updates, and the updates will be automatically feed through.

Inputs:
The following tables are inputs into the model. They are separated as variables one can update, or
constants that are constants

Variables

- Manual_Updates(V): This is a table to provide the impact of pipeline material coming to market. Due to BOM’s of pipeline materials not being available, estimates of pallets for therapeutics and raw materials are calculated by site, by therapeutics, by year.
- Months_on_Hand(V): This is a table with therapeutics and material sub groups inventory levels by site and the corresponding months of coverage. i.e. AML CHEM has X months of inventory
- Site_Mtrl_Grp_Stage (V): This table breaks down the different components of Drug production into three buckets: Drug Substance (DS), Drug Therapeutics (DP), and Finished Drug Therapeutics (FDP)
- Warehouse_Capacity_By_Type(V): This table provides the efficiency and capacity of each site by temperature storage type.
- make X, you will need Y quantity of Z material sub group
- Material_Master(V): This is the pallet quantity conversion and the temperature key. This is linked to the reports to break down the quantity of materials into pallet quantities.
- IDP_LDP_SS(V): This is a table of IDP and LDP therapeutics safety stock MOH by site.

Constants

- MPS_Summary_Ref_Part XXX (Where XXX is the warehouse site) (C): These are excel files linked to the database that showcase the following inputs to the model:
  - Total Demand- The downstream demand for that site for therapeutics by year
  - Total Supply- The supply determined to be manufactured at that site by year
  - Projected Bal. – The inventory used for risk mitigation purposes and bridges between next campaigns to ensure demand is met.
- Active_BOM(C): This is the BOMs for all therapeutics. This will provide the quantity in order to

Queries:
The queries will be assembled into the different segments of the Baseline model

Compiling and aggregating the inputs
• Union_All_MPS_Sites – Combines all MPS tables into one for ease of use.

Calculating the Raw Materials Needs (Labeled from 1 to 10 for their run rate)

• 1) Raw_Material_BOM_1_3_Initial- Adds the Site Name to the Union_All_MPS_Sites query to develop further processing
• Raw_Material_BOM_2_3_Trial – Compares the therapeutics supply for the year, and determines the raw materials by item by quantity to meet the supply required.
• 2) Raw_Material_BOM_2_3_Initial – Filters out the “Not Like KG or Not like L” so those materials can be broken out in another query.
• 2) Raw_Material_BOM_2_3_Initial_KG – Filters all “Like KG or Like L” so those materials can be timed times 1000.
• 3) Raw_Material_BOM_3_3_Palletzation – Divides the raw material calculated volumes into pallet quantities. Calculates the raw material MOH by the following formula:
  
  \[ \text{[Months on Hand]} \cdot \text{[Months On Hand]} \cdot \left( \frac{[20XXRS]^0.3}{12} \right) \]

  where the MOH is multiplied by the Ratio_Supply for that year.
• 3) Raw_Material_BOM_3_3_Palletzation_KG - Divides the raw material calculated volumes into pallet quantities. Calculates the raw material MOH by the following formula:
  
  \[ \text{[Months on Hand]} \cdot \text{[Months On Hand]} \cdot \left( \frac{[20XXRS]^0.3}{12} \right) \]

  where the MOH is multiplied by the Ratio_Supply for that year.
• 4) Temp_Raw_Material_2nd_Order_1_2 – Find the volumes from 1st order raw materials and the corresponding 2nd order raw materials required to manufacture the 1st order. Also filters out the therapeutics.
• 5) Raw_Material_2nd_Order_1_2 – Takes the raw materials calculated in Temp Raw_Material_2nd_Order_1_2 and determines the raw materials required to manufacture those materials. Filters out any items on the Union_All_MPS_Sites so it does not double count any therapeutics.
• 5) Raw_Material_2nd_Order_1_2_KG - Takes the raw materials calculated in Raw_Material_BOM_2_3_Initial and determines the raw materials required to manufacture those materials. Filters out any items on the Union_All_MPS_Sites so it does not double count any therapeutics.
• 6) Raw_Material_2nd_Order_2_2 – Divides the raw material calculated volumes into pallet quantities. Calculates the raw material MOH by the following formula:
  
  \[ \text{[Months on Hand]} \cdot \text{[Months On Hand]} \cdot \left( \frac{[20XXRS]^0.3}{12} \right) \]

  where the MOH is multiplied by the Ratio_Supply for that year.
• 6) Raw_Material_2nd_Order_2_2_KG – Divides the raw material calculated volumes into pallet quantities. Calculates the raw material MOH by the following formula:
  
  \[ \text{[Months on Hand]} \cdot \text{[Months On Hand]} \cdot \left( \frac{[20XXRS]^0.3}{12} \right) \]

  where the MOH is multiplied by the Ratio_Supply for that year.
• 7) Raw_Material_3rd_Order_1_2 – Finds the quantity of materials required to manufacture based on the 2nd Order raw materials. Removes any raw materials that are on the 1st and 2nd order raw material.
• 7) Raw_Material_3rd_Order_1_2_KG – Finds the quantity of materials required to manufacture based on the 2nd Order raw materials. Removes any raw materials that are on the 1st and 2nd order raw material.
8) Raw_Material_3rd_Order_2_3 – Filters out any raw materials that are on the 1st and 2nd order raw materials queries

8) Raw_Material_3rd_Order_2_3_KG - Filters out any raw materials that are on the 1st and 2nd order raw material queries.

9) Raw_Material_3rd_Order_3_3_Palletzation - Divides the raw material calculated volumes into pallet quantities. Calculates the raw material MOH by the following formula:
\[\text{ MOH } = \frac{\text{ Months on Hand} \times \text{ Months On Hand} \times \left(20XXRS \times 0.3\right)}{12}\]

9) Raw_Material_3rd_Order_3_3_Palletzation_KG - Divides the raw material calculated volumes into pallet quantities. Calculates the raw material MOH by the following formula:
\[\text{ MOH } = \frac{\text{ Months on Hand} \times \text{ Months On Hand} \times \left(20XXRS \times 0.3\right)}{12}\]

10) Total_ProjectedException_Balance_RM – This is the summation of all the Raw Material queries into one query.

**Strategic Safety Stock**

Total_ProjectedException_Balance – Filters the Union_All_MPS_Sites query for Projected Balance, and divides the projected balance quantity by the pallet quantity. This query provides the amount of finished therapeutics and Work In Progress (WIP) that will be stored to ensure demand is met. Rapid Response calculates this as the previous year’s projected balance + This year’s demand

Safety_Stock_IDP_LDP_SS – Multiplies the Raw Material IDP and LDP by the IDP_LDP_SS for the MOH safety stock for each site

**Work in Progress**

Total_Supply_WIP – Filters the Union_All_MPS_Sites query for Total Supply, and multiplies the total supply quantity by Months_On_Hand to have MOH worth of Work in Progress at each site, divides by the pallet quantity. This query provides the amount of finished therapeutics and Work In Progress (WIP) that will be stored to ensure demand is met.

**Outputs:**

FINAL_WAREHOUSE_CAPACITY_RESULTS - This is the final table for the baseline model. It adjusts the total warehouse capacity needs found in Total_ProjectedException_Balance_ALL by dividing each sites warehouse needs by warehouse efficiencies.

Total_ProjectedException_Balance_ALL – This is the overall sum of all pallets required to be stored. This combines the Total_ProjectedException_Balance and the Total_Supply_WIP and Total_ProjectedException_Balance_RM and the Safety_Stock_LDP into one

**Risk Assessment**

This module of the database takes the baseline model results, and performs the playbook risk scenarios for each site’s impacts on the other sites. This will showcase what the impacts of a site’s going down on
other sites warehouses. To run this module, simply run the UPDATE_RISK_SITUATIONS, which is a macro that will utilize the FINAL_WAREHOUSE_CAPACITY_RESULTS and simulate the

**Inputs:**
- Risk_Mitigation (V) – Table that determines where each therapeutics by site will be transferred to which site. Note that some therapeutics will not impact other sites, as they have inventory that will be the risk mitigation or sub-contractors.
- FINAL_WAREHOUSE_CAPACITY_RESULTS - This is the final table from the baseline model.

**Queries:**
- Update_Risk_XXX- This make table query simply takes the FINAL_WAREHOUSE_CAPACITY_RESULTS and creates the Risk_Mitigation_XXX table in order to have that sites risk mitigations impacts performed on it.
- Update_Risk_Mitigation_XXX – This update query utilizes the Risk Mitigation table to update the tables created by the Update_Risk_XXX site.

**Outputs:**
- Risk_Mitigation_XXX – This is the tables updated through the Update_Risk_Mitigation_XXX. It provides the impacts of that Sites risk mitigation impacts on other sites.

**Optimistic and Pessimistic Scenarios**
This module will run optimistic and pessimistic scenarios on the base line model. It

**Inputs:**
- Mtrl_Grp_Type (V)- For each therapeutics, it assigns a multiplier by year for the optimistic and pessimistic scenarios by year. Using chaos theory, the scenarios should diverge in bigger ranges after each year.
- FINAL_WAREHOUSE_CAPACITY_RESULTS (C) - This is the final table from the baseline model.
- Warehouse_Capacity_By_Type_Full_Efficiency (V) – This is a copy of the Warehouse_Capacity_By_Type, but the efficiencies are adjusted to .85, the ideal state of warehouse efficiencies.

**Queries & Outputs:**
- Optimistic Case – Utilizes FINAL_WAREHOUSE_CAPACITY_RESULTS and multiples the storage requirements by the multiplier for optimistic scenarios for each year.
- Pessimistic Case - Utilizes FINAL_WAREHOUSE_CAPACITY_RESULTS and multiples the storage requirements by the multiplier for pessimistic scenarios for each year.
- Warehouse_Capacity_full_Capacity - Utilizes FINAL_WAREHOUSE_CAPACITY_RESULTS and divides the storage requirements by the efficiencies for the updated warehouse efficiencies.